A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).

Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pottecher, J., Sato, V. A. H., Pletan, Y., Comenducci, A., Desort-Henin, V., Jandrot-Perrus, M., Binay, S., Meilhoc, A., Avenard, G. Tags: 02.01 - Acute critical care Source Type: research